NCT06408857 - Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population | Biotech Hunter

Enrollment

123

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Healthy Volunteers

Interventions

DRUG

MAM01 300 mg SC

MAM01 300 mg will be administered SC

DRUG

MAM01 300 mg IM

MAM01 300 mg will be administered IM route

DRUG

MAM01 2000 mg IV

MAM01 2000 mg will be administered IV

DRUG

MAM01 190 mg SC

MAM01 190 mg will be administered SC

DRUG

MAM01 225 mg SC

MAM01 225 mg will be administered SC

DRUG

MAM01 150 mg SC

MAM01 150 mg will be administered SC

DRUG

MAM01 150 mg IM

MAM01 150 mg will be administered IM

DRUG

MAM01 150 mg IV

MAM01 150 mg will be administered IV

DRUG

Placebo SC

Placebo will be administered SC

DRUG

Placebo IV

Placebo will be administered IV.

DRUG

Placebo IM

Placebo will be administered IM

Trial Locations (2)

749

RECRUITING

IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road, Tororo

10005

RECRUITING

JCRC-Joint Clinical Research Centre, Kampala